Idera Pharmaceuticals, Inc. (IDRA)
-NasdaqCM 0.68 
0.02(2.16%) May 24, 3:59PM EDT
| Prev Close: | 0.70 |
|---|
| Open: | 0.71 |
|---|
| Bid: | 0.65 x 1000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.40 |
|---|
| Beta: | 2.38 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.68 - 0.74 |
|---|
| 52wk Range: | 0.19 - 1.22 |
|---|
| Volume: | 84,185 |
|---|
| Avg Vol (3m): | 174,509 |
|---|
| Market Cap: | 18.80M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.71 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Fri, May 24)
- IDERA PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Tue, May 21)
- Idera Pharmaceuticals Reports First Quarter 2013 Financial ResultsBusiness Wire(Wed, May 15)
- IDERA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Thu, May 9)
- Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque PsoriasisBusiness Wire(Wed, May 8)
- Idera Pharmaceuticals Announces Closing of Common Share OfferingBusiness Wire(Tue, May 7)
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Tue, May 7)
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Thu, May 2)
- Idera Pharmaceuticals raises $16.5M in a common stock and warrant offeringtheflyonthewall.com(Thu, May 2)
- Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and WarrantsBusiness Wire(Wed, May 1)
- Idera Pharmaceuticals files to sell $12.5M in common stock and warrantstheflyonthewall.com(Tue, Apr 23)
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Mon, Apr 22)
- Idera Announces Clinical Development Progress in Its Autoimmune Diseases ProgramBusiness Wire(Mon, Apr 1)
- Idera stock plummets 20 percent as company faces possible liquidationat bizjournals.com(Wed, Mar 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 392.09 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.43 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates.
View More